<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Pelvic Inflammatory Disease (PID) ‚Äî One‚ÄëPage Primary Care Algorithm (CKS 2024)</title>
  <style>
    /* ---------- Design Tokens ---------- */
    :root {
      --bg: #0b0c10;
      --panel: #121319;
      --muted: #7c869b;
      --text: #e9ecf1;
      --accent: #5b9cff;
      --accent-2: #5dffa8;
      --danger: #ff6b6b;
      --warning: #ffb74a;
      --ok: #4cd97b;
      --shadow: 0 10px 30px rgba(0,0,0,.35);
      --radius: 16px;
    }
    @media (prefers-color-scheme: light) {
      :root { 
        --bg: #f6f7fb; 
        --panel: #ffffff; 
        --muted:#5b657a; 
        --text:#0b1020; 
        --shadow: 0 10px 25px rgba(17, 23, 41, .08); 
      }
    }

    /* ---------- Base ---------- */
    * { box-sizing: border-box; }
    html, body { height: 100%; }
    body {
      margin: 0; font: 500 16px/1.55 system-ui, -apple-system, Segoe UI, Roboto, Inter, Arial, sans-serif;
      color: var(--text); background: radial-gradient(1200px 800px at 0% -10%, rgba(91,156,255,.08), transparent 40%), var(--bg);
    }
    a { color: var(--accent); text-decoration: none; }
    h1, h2, h3 { line-height: 1.15; margin: 0 0 .4rem; }
    h1 { font-size: clamp(1.4rem, 2.6vw + .6rem, 2.2rem); }
    h2 { font-size: clamp(1.05rem, 1.2vw + .7rem, 1.35rem); letter-spacing:.2px; }
    p { margin: .25rem 0 .75rem; color: var(--text); }
    ul { margin: .35rem 0 .9rem 1.25rem; padding: 0; }
    li { margin: .25rem 0; }
    .muted { color: var(--muted); }
    .small { font-size: .9rem; }

    /* ---------- Layout ---------- */
    .wrap { max-width: 1100px; margin: 0 auto; padding: 24px; }
    header.hero { position: sticky; top: 0; z-index: 10; backdrop-filter: saturate(1.1) blur(8px); background: color-mix(in oklab, var(--bg) 86%, transparent); border-bottom: 1px solid color-mix(in oklab, var(--muted) 25%, transparent); }
    .hero-inner { display: grid; grid-template-columns: 1fr auto; gap: 16px; align-items: center; max-width: 1100px; margin: 0 auto; padding: 16px 24px; }
    .tagline { color: var(--muted); }

    .toolbar { display: flex; gap: 8px; flex-wrap: wrap; }
    .btn { appearance: none; border: none; padding: 10px 14px; border-radius: 12px; background: var(--panel); color: var(--text); box-shadow: var(--shadow); cursor: pointer; transition: transform .06s ease, background .2s ease; font-weight: 650; }
    .btn:hover { transform: translateY(-1px); }
    .btn-primary { background: linear-gradient(135deg, var(--accent), #7ec8ff); color: #00122a; }
    .btn-outline { background: transparent; border: 1px solid color-mix(in oklab, var(--accent) 35%, transparent); }

    .grid { display: grid; gap: 18px; grid-template-columns: repeat(12, 1fr); margin-top: 20px; }
    .col-8 { grid-column: span 8; }
    .col-4 { grid-column: span 4; }
    .col-6 { grid-column: span 6; }
    .col-12 { grid-column: span 12; }

    @media (max-width: 980px) {
      .col-8, .col-4, .col-6 { grid-column: span 12; }
    }

    /* ---------- Card ---------- */
    .card { background: var(--panel); border: 1px solid color-mix(in oklab, var(--muted) 18%, transparent); border-radius: var(--radius); box-shadow: var(--shadow); padding: 18px 18px; }
    .card h2 { display: flex; align-items: center; gap: 10px; }
    .eyebrow { text-transform: uppercase; letter-spacing: .14em; font-size: .75rem; color: var(--muted); margin-bottom: .3rem; }

    .badge { display: inline-flex; align-items: center; gap: .5ch; background: rgba(91,156,255,.12); color: var(--accent); border: 1px solid color-mix(in oklab, var(--accent) 40%, transparent); padding: 6px 10px; border-radius: 999px; font-weight: 650; font-size: .85rem; }
    .badge.ok { background: rgba(76,217,123,.12); color: var(--ok); border-color: color-mix(in oklab, var(--ok) 40%, transparent); }
    .badge.warn { background: rgba(255,183,74,.12); color: var(--warning); border-color: color-mix(in oklab, var(--warning) 40%, transparent); }
    .badge.danger { background: rgba(255,107,107,.12); color: var(--danger); border-color: color-mix(in oklab, var(--danger) 40%, transparent); }

    /* ---------- Pills & Regimens ---------- */
    .regimen { display: grid; grid-template-columns: 28px 1fr; align-items: flex-start; gap: 10px; padding: 10px 12px; border-radius: 12px; border: 1px dashed color-mix(in oklab, var(--muted) 35%, transparent); margin: 8px 0; }
    .regimen .dot { width: 18px; height: 18px; border-radius: 50%; background: var(--accent); margin-top: 3px; }
    .regimen.alt .dot { background: var(--warning); }
    .regimen.moxi .dot { background: #7b61ff; }

    .k { display: inline-block; border-radius: 8px; padding: 2px 8px; background: color-mix(in oklab, var(--muted) 12%, transparent); border: 1px solid color-mix(in oklab, var(--muted) 20%, transparent); font-weight: 700; }

    /* ---------- Callouts ---------- */
    .callout { display: grid; grid-template-columns: 28px 1fr; gap: 12px; padding: 12px 14px; border-left: 4px solid var(--accent); border-radius: 12px; background: color-mix(in oklab, var(--accent) 10%, transparent); }
    .callout.danger { border-left-color: var(--danger); background: color-mix(in oklab, var(--danger) 12%, transparent); }
    .callout.warn { border-left-color: var(--warning); background: color-mix(in oklab, var(--warning) 12%, transparent); }

    /* ---------- Sticky nav ---------- */
    .nav { position: sticky; top: 76px; display: grid; gap: 12px; }
    .nav a { display: block; padding: 12px 14px; border-radius: 12px; border: 1px solid color-mix(in oklab, var(--muted) 20%, transparent); background: var(--panel); color: var(--text); box-shadow: var(--shadow); font-weight: 650; }
    .nav a:hover { outline: 2px solid color-mix(in oklab, var(--accent) 40%, transparent); }

    /* ---------- Footer ---------- */
    footer { margin: 24px auto 40px; color: var(--muted); text-align: center; }

    /* ---------- Print ---------- */
    @page { size: A4 portrait; margin: 12mm; }
    @media print {
      header.hero, .nav, .toolbar { display:none !important; }
      body { background: white; }
      .wrap { padding: 0; }
      .card { break-inside: avoid; box-shadow: none; }
      a { color: black; text-decoration: none; }
    }
  </style>
</head>
<body>
  <header class="hero">
    <div class="hero-inner">
      <div>
        <h1>Pelvic Inflammatory Disease (PID) ‚Äî One‚ÄëPage Primary Care Algorithm</h1>
        <div class="tagline">NICE CKS (last revised June¬†2024) ‚Ä¢ Purpose: rapid memory aid & decision support in consultations</div>
      </div>
      <div class="toolbar">
        <button class="btn btn-primary" onclick="window.print()">üñ®Ô∏è Print</button>
        <a class="btn btn-outline" href="#antibiotics">üíä Regimens</a>
        <a class="btn btn-outline" href="#admit">üè• Admit</a>
        <a class="btn btn-outline" href="#followup">‚è±Ô∏è 72‚Äëhour Review</a>
      </div>
    </div>
  </header>

  <main class="wrap">
    <div class="grid">
      <!-- Left column: content -->
      <section class="col-8">
        <article class="card" id="recognise">
          <div class="eyebrow">Step 1</div>
          <h2>Recognise & Assess <span class="badge">Do not delay treatment for swab results</span></h2>
          <ul>
            <li><strong>Typical symptoms</strong>: new bilateral pelvic/lower abdo pain; deep dyspareunia; abnormal bleeding (IMB, PCB, heavy); mucopurulent discharge; ¬± systemic symptoms (fever, nausea/vomiting, malaise); consider RUQ/shoulder pain ‚Üí perihepatitis.</li>
            <li><strong>Risk</strong>: sexually active (low threshold even if monogamous), recent new partner (&lt;3‚ÄØmonths), multiple partners, no barrier contraception, prior PID/STI, recent uterine instrumentation (TOP, IUD &lt;3‚ÄØweeks, HSG/hysteroscopy, IVF).</li>
            <li><strong>Exam</strong>: lower abdo tenderness, cervical motion/uterine/adnexal tenderness ¬± mass, mucopurulent discharge or cervical friability.</li>
            <li><strong>Investigations (don‚Äôt delay antibiotics)</strong>:
              <ul>
                <li><span class="k">Pregnancy test</span> ‚Äî exclude ectopic.</li>
                <li><span class="k">Vaginal/endocervical swabs</span> ‚Äî chlamydia & gonorrhoea; consider <em>M. genitalium</em> where available.</li>
                <li><span class="k">Wet‚Äëmount</span> for pus cells if available; absent cells make PID unlikely.</li>
                <li><span class="k">Bloods</span> (FBC, ESR/CRP) if clinically useful; consider HIV, hepatitis, syphilis per STI screen.</li>
              </ul>
            </li>
          </ul>
          <div class="callout warn" id="admit">
            <div>‚ö†Ô∏è</div>
            <div>
              <strong>Admit / Urgent referral now if</strong>: pregnant or ectopic suspected; severe systemic illness or adnexal mass (abscess/peritonitis); systemically unwell with uncertain diagnosis; unable to tolerate or follow outpatient care.
            </div>
          </div>
        </article>

        <article class="card" id="initial">
          <div class="eyebrow">Step 2</div>
          <h2>Immediate Primary‚ÄëCare Management</h2>
          <ul>
            <li><strong>Start empirical antibiotics immediately once working diagnosis made.</strong> Ideally take STI tests first, but <em>do not wait</em>.</li>
            <li><strong>Analgesia</strong>: paracetamol and/or ibuprofen if appropriate.</li>
            <li><strong>Sexual health service</strong>: arrange/advise for STI screen, treatment, and contact tracing of partners in last 6 months.</li>
            <li><strong>Sexual activity</strong>: abstain until patient and partners complete treatment, are symptom‚Äëfree, and test‚Äëof‚Äëcure done if indicated; use barrier if sex cannot be avoided.</li>
          </ul>
          <div class="callout" id="iud">
            <div>üß∑</div>
            <div>
              <strong>IUD in situ</strong>: if mild‚Äìmoderate, <em>leave in</em> provided clinical improvement within 48‚Äì72‚ÄØh; remove if no improvement. If severe at presentation ‚Üí remove. If removed, consider emergency contraception & ongoing contraception plan.
            </div>
          </div>
        </article>

        <article class="card" id="antibiotics">
          <div class="eyebrow">Step 3</div>
          <h2>Empirical Antibiotic Regimens</h2>

          <div class="regimen">
            <div class="dot"></div>
            <div>
              <strong>First‚Äëline (use regardless of gonorrhoea risk; essential if high risk)</strong><br/>
              <span class="k">Ceftriaxone 1‚ÄØg IM √ó1</span> 
              ‚Üí <span class="k">Doxycycline 100‚ÄØmg PO BD √ó14‚ÄØdays</span> 
              + <span class="k">Metronidazole 400‚ÄØmg PO BD √ó14‚ÄØdays</span>
            </div>
          </div>

          <div class="regimen alt">
            <div class="dot"></div>
            <div>
              <strong>Second‚Äëline (if ceftriaxone unsuitable & low gonorrhoea risk)</strong><br/>
              <span class="k">Ofloxacin 400‚ÄØmg PO BD √ó14‚ÄØdays</span> + <span class="k">Metronidazole 400‚ÄØmg PO BD √ó14‚ÄØdays</span><br/>
              <em>OR</em> <span class="k">Levofloxacin 500‚ÄØmg PO OD √ó14‚ÄØdays</span> + <span class="k">Metronidazole 400‚ÄØmg PO BD √ó14‚ÄØdays</span><br/>
              <em>OR</em> <span class="k">Moxifloxacin 400‚ÄØmg PO OD √ó14‚ÄØdays</span>
            </div>
          </div>

          <div class="regimen moxi">
            <div class="dot"></div>
            <div>
              <strong>If <em>Mycoplasma genitalium</em> positive</strong><br/>
              <span class="k">Moxifloxacin 400‚ÄØmg PO OD √ó14‚ÄØdays</span>
            </div>
          </div>

          <div class="regimen">
            <div class="dot"></div>
            <div>
              <strong>If first‚Äë & second‚Äëline not tolerated/contraindicated</strong><br/>
              <span class="k">Ceftriaxone 1‚ÄØg IM √ó1</span> + <span class="k">Azithromycin 1‚ÄØg PO weekly √ó2 doses</span>
            </div>
          </div>

          <div class="callout warn">
            <div>üí°</div>
            <div>
              <strong>Fluoroquinolones</strong>: prescribe only when other recommended antibiotics are inappropriate (MHRA safety restrictions). Provide patient safety information and consider risks (tendon damage, aortic aneurysm/dissection, QT prolongation, glucose dysregulation, heart valve regurgitation). Check BNF/eMC for interactions and cautions.
            </div>
          </div>
        </article>

        <article class="card" id="followup">
          <div class="eyebrow">Step 4</div>
          <h2>Follow‚Äëup & Test‚Äëof‚ÄëCure</h2>
          <h3>72‚Äëhour review</h3>
          <ul>
            <li>Assess symptom response. If not improving ‚Üí check adherence, re‚Äëevaluate diagnosis/complications, check culture/sensitivities, consider urgent admission.</li>
            <li>If metronidazole intolerance and symptoms are mild‚Äìmoderate ‚Üí stop metronidazole but continue other agents.</li>
          </ul>
          <h3>2‚Äì4‚ÄØweeks after completion</h3>
          <ul>
            <li>Confirm adherence & recovery; ensure partners screened/treated; advise barrier contraception going forward.</li>
            <li>Repeat pregnancy test and arrange <strong>test‚Äëof‚Äëcure (TOC)</strong> when indicated:</li>
          </ul>
          <div class="grid">
            <div class="col-6">
              <div class="card" style="padding:12px">
                <div class="eyebrow">Routine TOC</div>
                <ul>
                  <li><strong>Gonorrhoea</strong>: repeat test <span class="k">2‚Äì4‚ÄØweeks</span> after treatment.</li>
                </ul>
              </div>
            </div>
            <div class="col-6">
              <div class="card" style="padding:12px">
                <div class="eyebrow">Conditional TOC</div>
                <ul>
                  <li><strong>Chlamydia</strong>: repeat at <span class="k">3‚Äì5‚ÄØweeks</span> if persisting symptoms/poor adherence or contact tracing concerns.</li>
                  <li><strong><em>M. genitalium</em></strong>: repeat at <span class="k">4‚ÄØweeks</span> after treatment.</li>
                </ul>
              </div>
            </div>
          </div>
          <ul>
            <li>Also perform TOC if persistent symptoms, resistance/unknown sensitivities, poor adherence, or risk of reinfection.</li>
          </ul>
        </article>

        <article class="card" id="partners">
          <div class="eyebrow">Step 5</div>
          <h2>Partner Management</h2>
          <ul>
            <li>Advise all <strong>current & recent partners (past 6‚ÄØmonths)</strong> to attend a specialist sexual health service for screening, treatment, and contact tracing.</li>
            <li>If a partner cannot attend: offer GC/CT screening; for male partners give empirical <span class="k">Doxycycline 100‚ÄØmg PO BD √ó7‚ÄØdays</span> while awaiting results.</li>
            <li>If the index has confirmed <em>M. genitalium</em>, screen partners (if available) and treat both if positive.</li>
            <li><strong>Abstain from sex</strong> until all parties complete antibiotics, are symptom‚Äëfree, and TOC done when required.</li>
          </ul>
        </article>

        <article class="card">
          <h2>Core Principle</h2>
          <p class="badge ok">Low threshold to diagnose ‚Ä¢ Start antibiotics immediately ‚Ä¢ Involve sexual health services ‚Ä¢ Review early</p>
        </article>
      </section>

      <!-- Right column: quick nav & notes -->
      <aside class="col-4">
        <nav class="nav">
          <a href="#recognise">üîé Recognise & Assess</a>
          <a href="#admit">üè• Admit / Refer Now</a>
          <a href="#initial">üß≠ Immediate Management</a>
          <a href="#antibiotics">üíä Antibiotic Regimens</a>
          <a href="#iud">üß∑ IUD in situ</a>
          <a href="#followup">‚è±Ô∏è Follow‚Äëup & TOC</a>
          <a href="#partners">üë• Partner Management</a>
        </nav>

        <section class="card">
          <div class="eyebrow">Safety & Prescribing</div>
          <h2>Check before you prescribe</h2>
          <ul>
            <li>Review BNF/eMC for contraindications, interactions, and adverse effects (ceftriaxone, doxycycline, metronidazole, ofloxacin/levofloxacin/moxifloxacin, azithromycin).</li>
            <li>Fluoroquinolone caution: tendon injury, aortic aneurysm/dissection, QT prolongation, glycaemic disturbance, valve regurgitation; use only if alternatives inappropriate.</li>
            <li>Document <strong>pregnancy status</strong> before tetracyclines/quinolones; avoid tetracyclines in pregnancy/breastfeeding.</li>
            <li>Advise no alcohol with metronidazole; counsel on photosensitivity with doxycycline.</li>
          </ul>
        </section>

        <section class="card">
          <div class="eyebrow">Notes</div>
          <ul>
            <li>Negative swabs <em>do not</em> exclude PID ‚Äî complete the antibiotic course to reduce long‚Äëterm complications.</li>
            <li>Be alert for complications: tubo‚Äëovarian abscess, pelvic peritonitis/sepsis, Fitz‚ÄëHugh‚ÄëCurtis syndrome.</li>
            <li>Consider differentials: ectopic pregnancy, appendicitis, UTI/pyelonephritis/renal colic, ovarian cyst complications, endometriosis, GI causes, mittelschmerz.</li>
            <li>Align with local antimicrobial guidance and sexual health pathways.</li>
          </ul>
        </section>
      </aside>
    </div>

    <footer>
      Rapid reference derived from NICE CKS: Pelvic inflammatory disease ‚Äî primary care management (last revised June¬†2024). This page is a practical aide‚Äëm√©moire and does not replace clinical judgement or full guidance.
    </footer>
  </main>

</body>
</html>
